C. Mattsson

发表

Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.

K. Hansson, O. Fjellström, D. Gustafsson, 2014, Bioorganic & medicinal chemistry letters.

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

L. Rydén, L. Grip, P. Sjöquist, 1996, Cardiovascular research.

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

P. Held, B. Karlson, U. Eriksson, 2005, Thrombosis research.

Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects

M. Wolzt, U. Eriksson, L. Frison, 2002, Thrombosis and Haemostasis.

The use of the Chandler loop to examine the interaction potential of NXY‐059 on the thrombolytic properties of rtPA on human thrombi in vitro

N. Booth, N. Mutch, A. R. Green, 2008, British journal of pharmacology.

Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)

V. Nerme, J. Björkman, C. Mattsson, 2002, Thrombosis and Haemostasis.

Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP‐ and thrombin‐induced human platelet activation

T. Lindahl, C. Mattsson, S. Nylander, 2004, British journal of pharmacology.

Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.

J. Deinum, T. Inghardt, C. Mattsson, 2009, Thrombosis and haemostasis.

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.

C. Mattsson, E. Holmer, S. Nilsson, 1982, Thrombosis research.

Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action

C. Mattsson, S. Nylander, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

T. Griggs, M. Read, K. Brinkhous, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes

S. Pehrsson, H. Sörensen, I. Nilsson, 1998, Thrombosis and Haemostasis.

Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis

J. Björkman, C. Mattsson, J. Ulvinge, 1997 .

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.

J. Mehta, W. Nichols, T. Saldeen, 1998, Journal of cardiovascular pharmacology.

Antithrombotic Effect of Two Low Molecular Weight Thrombin Inhibitors and a Low-Molecular Weight Heparin in a Caval Vein Thrombosis Model in the Rat

B. Eriksson, B. Risberg, C. Mattsson, 1997, Thrombosis and Haemostasis.

Pharmacokinetics of Heparin and Low Molecular Weight Heparin Fragment (Fragmin®) in Rabbits with Impaired Renal or Metabolic Clearance

C. Mattsson, M. Palm, 1987, Thrombosis and Haemostasis.

Melagatran attenuates fibrin and platelet deposition in a porcine coronary aartery over‐stretch injury model

L. Grip, S. Carlsson, C. Mattsson, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.

V. Nerme, J. Björkman, C. Mattsson, 2005, Thrombosis research.

Characterisation of species differences in the platelet ADP and thrombin response.

T. Lindahl, C. Mattsson, S. Nylander, 2006, Thrombosis research.

The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation.

T. Lindahl, C. Mattsson, S. Nylander, 2003, Thrombosis research.

A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.

G. Pohl, C. Mattsson, K. Wikström, 1993, Thrombosis research.

Tissue plasminogen activator mutants lacking the growth factor domain and the first kringle domain: II: Enzymatic properties in plasma and in vivo thrombolytic activity and clearance rates in rabbits

C. Sterky, G. Pohl, C. Mattsson, 1991 .

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.

L. Rydén, N. Hatori, R. Nordlander, 1998, Journal of pharmacological and toxicological methods.

Antithrombotic Effects of Heparin Oligosaccharides

C. Mattsson, E. Holmer, M. Palm, 1989, Annals of the New York Academy of Sciences.

Turnover of tissue plasminogen activator in normal and hepatectomized rabbits.

L. Häggroth, C. Mattsson, S. Nilsson, 1985, Thrombosis research.

Pharmacokinetics and Coronary Thrombolytic Properties of Two Human Tissue‐Type Plasminogen Activator Variants Lacking the Finger‐Like, Growth Factor‐Like, and First Kringle Domains (Amino Acids 6–173) in a Canine Model

D. Collen, G. Pohl, C. Mattsson, 1990, Journal of cardiovascular pharmacology.

Inhibition of angiogenesis by heparin fragments in the presence of hydrocortisone

C. Mattsson, C. Svahn, M. Palm, 1992 .

Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample

T. Lindahl, C. Mattsson, K. Wåhlander, 2001, Thrombosis and Haemostasis.

Inhibition of the human tissue plasminogen activator in plasma from different species.

L. Häggroth, C. Mattsson, J. Friberg, 1984, Thrombosis research.

Dissolution Of Thrombi By Tissue Plasminogen Activator, Urokinase And Streptokinase In An Artificial Circulating System

C. Mattsson, P. Wallén, V. Nyberg-Arrhenius, 1981, Thrombosis and Haemostasis.

Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III.

M. Hoylaerts, D. Collen, C. Mattsson, 1985, The Journal of clinical investigation.

Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.

L. Häggroth, C. Mattsson, S. Nilsson, 1983, Thrombosis research.

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.

W. Nichols, T. Saldeen, R. Schofield, 1992, Journal of the American College of Cardiology.

Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock

A. Larsson, A. Nordgren, S. Basu, 2000, Expert opinion on investigational drugs.

Melagatran, a Low Molecular Weight Thrombin Inhibitor, Counteracts Endotoxin-induced Haemodynamic and Renal Dysfunctions in the Pig

T. Saldeen, M. Eriksson, C. Mattsson, 1998, Thrombosis and Haemostasis.

Effect on haemostasis of intravenous injection of alpha 2-antiplasmin in cats treated with streptokinase.

C. Mattsson, S. Nilsson, M. Einarsson, 1983, Thrombosis research.

Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.

J. Deinum, C. Mattsson, S. Nylander, 2001, Thrombosis research.

Bleeding Times in Rats Treated with Heparin, Heparin Fragments of High and Low Anticoagulant Activity and chemically Modified Heparin Fragments of Low Anticoagulant Activity

C. Mattsson, M. Palm, Michael Weber, 1990, Thrombosis and Haemostasis.

Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin.

C. Mattsson, M. Palm, 1987, Thrombosis research.

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

Christer Mattsson, Michael Wolzt, David Gustafsson, 2003, Journal of the American College of Cardiology.

Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.

L. Häggroth, I. Nilsson, C. Mattsson, 1986, Thrombosis research.

Elimination of Native and Carbohydrate-Modified Tissue Plasminogen Activator in Rabbits

L. Häggroth, C. Mattsson, M. Einarsson, 1989, Thrombosis and Haemostasis.

Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs

A. Larsson, M. Eriksson, T. Saldeen, 2000, Acta anaesthesiologica Scandinavica.

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.

S. Carlsson, C. Mattsson, M. Elg, 2002, Thrombosis research.

Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.

W. Nichols, T. Saldeen, C. Mattsson, 1996, The Journal of pharmacology and experimental therapeutics.

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.

W. Nichols, T. Saldeen, R. Wallin, 1995, Cardiovascular Research.

Antithrombotic Properties Of A Low Molecular Weight Heparin

C. Mattsson, C. Svahn, E. Holmer, 1981, Thrombosis and Haemostasis.

Crystal structure of pentastrontium tris(phosphate) bromide, Sr5(PO4)3Br and of pentabarium tris(phosphate) bromide Ba5(PO4)3Br, two bromoapatites

S. Lidin, C. Mattsson, P. Alberius-Henning, 2000 .